Oppenheimer (NYSE:OPY – Get Free Report) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Monday.
Oppenheimer Stock Down 0.9 %
NYSE OPY traded down $0.60 during trading on Monday, hitting $68.22. 24,693 shares of the company traded hands, compared to its average volume of 23,209. The company has a market capitalization of $704.71 million, a P/E ratio of 10.71 and a beta of 1.14. The business has a fifty day simple moving average of $65.36 and a 200 day simple moving average of $57.14. Oppenheimer has a 12 month low of $36.93 and a 12 month high of $73.12. The company has a current ratio of 1.29, a quick ratio of 0.80 and a debt-to-equity ratio of 0.13.
Oppenheimer (NYSE:OPY – Get Free Report) last issued its quarterly earnings results on Friday, January 31st. The financial services provider reported $0.92 EPS for the quarter. Oppenheimer had a return on equity of 8.76% and a net margin of 5.00%.
Institutional Trading of Oppenheimer
About Oppenheimer
Oppenheimer Holdings Inc operates as a middle-market investment bank and full-service broker-dealer in the Americas, Europe, the Middle East, and Asia. The company provides brokerage services covering corporate equity and debt securities, money market instruments, exchange-traded options and futures contracts, municipal bonds, mutual funds, exchange-traded funds, and unit investment trusts; financial and wealth planning services; and margin lending services.
Featured Articles
- Five stocks we like better than Oppenheimer
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- How to Invest in Small Cap Stocks
- The Role Economic Reports Play in a Successful Investment Strategy
- These Are the Dividend Stocks Insiders Bought in January
- What Are Some of the Best Large-Cap Stocks to Buy?
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Receive News & Ratings for Oppenheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oppenheimer and related companies with MarketBeat.com's FREE daily email newsletter.